Sulforaphane attenuates EGFR signaling in NSCLC cells
نویسندگان
چکیده
منابع مشابه
EGFR expression in NSCLC
E pidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is frequently overexpressed in nonsmall cell lung cancer (NSCLC). These receptors play an important role in tumour cell survival and activated phosphorylated EGFR results in the phosphorylation of downstream proteins that cause cell proliferation, invasion, metastasis, and inhibition of apoptosis. Expression appears to be dep...
متن کاملTtf1 Ihc Predicts Egfr Status in Nsclc
Lung cancers are the leading cause of cancer-related mortality in the developed world. In recent decades, great strides have been made in treating this group of diseases, including improved surgical management, increased early detection, and newly available targeted therapies1,2. The epidermal growth factor receptor (egfr) is the most well-characterized biologic target in lung cancer3. Activati...
متن کاملGefitinib Treatment in EGFR Mutated Caucasian NSCLC
INTRODUCTION In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (previously published). Here, we report EGFR mutation analyses of plasma-derived, circulating-free tumor DNA. METHODS Mandatory tumor and duplicate ...
متن کاملEGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
EGF receptor (EGFR) promotes tumor growth as well as radio- and chemoresistance in various human malignancies including squamous cell carcinomas (SCC). In addition to deactivation of prosurvival signaling, cetuximab-mediated EGFR targeting might concomitantly induce self-attenuating signaling bypasses. Identification of such bypass mechanisms is key to improve the efficacy of targeted approache...
متن کاملJUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.
Mutations or deletions in exons 18-21 in the EGFR) are present in approximately 15% of tumors in patients with non-small cell lung cancer (NSCLC). They lead to activation of the EGFR kinase domain and sensitivity to molecularly targeted therapeutics aimed at this domain (gefitinib or erlotinib). These drugs have demonstrated objective clinical response in many of these patients; however, invari...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Biomedical Science
سال: 2015
ISSN: 1423-0127
DOI: 10.1186/s12929-015-0139-x